Understanding how specific genes influence pancreatic cancer growth and types
Lineage specifiers governing pancreatic cancer growth and molecular subtype
This study is looking at a tough type of pancreatic cancer to see if it can be divided into two groups based on how certain genes behave, which could help find better treatments that are more suited to each person's cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-10977302 on NIH RePORTER |
What this research studies
This research investigates pancreatic ductal adenocarcinoma (PDAC), a highly aggressive form of cancer with a very low survival rate. It aims to classify PDAC into two main subtypes, Classical and Basal-like, based on the expression of specific genes that influence cancer cell behavior. By analyzing human samples, the study seeks to uncover the molecular mechanisms that differentiate these subtypes and identify potential vulnerabilities for targeted therapies. This could lead to more effective treatment options tailored to the specific characteristics of a patient's cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma, particularly those with Classical or Basal-like subtypes.
Not a fit: Patients with other types of pancreatic cancer or those without a confirmed diagnosis of PDAC may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of targeted therapies that improve survival rates and treatment responses for patients with pancreatic cancer.
How similar studies have performed: Previous research has shown promise in understanding cancer subtypes and their implications for treatment, suggesting that this approach could yield significant insights.
Where this research is happening
Salt Lake City, United States
- University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Snyder, Eric Lee — University of Utah
- Study coordinator: Snyder, Eric Lee
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.